Luminopia’s Amblyopia Treatment Gains Coverage from Highmark

Digital health company Luminopia has obtained coverage approval from Highmark for its FDA-approved therapy for children with amblyopia, a significant condition affecting children’s eyesight. By engaging children in therapeutic video content, Luminopia offers a unique alternative to traditional treatment methods. Highmark’s approval of coverage underscores the unfulfilled need for effective therapies and the potential benefits of Luminopia’s technology.